Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce?
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Loading...